银屑病系统治疗不良事件的性别差异:瑞士银屑病登记处十年数据
基于瑞士银屑病登记处(SDNTT)十年数据,纳入791例中重度银屑病成人患者(女性290例),比较传统系统治疗(CST)与生物制剂的不良事件(ADR)发生率。CST的ADR率是生物制剂的2.2倍,停药率是8.0倍;女性在所有治疗中ADR率显著高于男性(CST为1.8倍,生物制剂为2.0倍),提示需考虑性别分层。
要点
- CST的ADR率(40.43/100患者年)显著高于生物制剂(18.22/100患者年)。
- 女性总体ADR率显著高于男性,CST为1.8倍,生物制剂为2.0倍。
- 女性多数CST的药物相关停药率更高,生物制剂严重不良事件率无显著差异。
核心结论
- 女性与显著更高的ADR率和药物相关停药率相关,银屑病个体化管理研究应考虑性别分层。
研究设计与样本
- 基于瑞士银屑病登记处(SDNTT)的十年数据,纳入791例需系统治疗的中重度银屑病成人患者(女性290例,平均年龄46岁)。
- 358例(45%)接受传统系统治疗(CST),433例(55%)接受生物制剂。
- ADR按MedDRA术语分类,通过计算每100患者年的事件率评估安全性。
主要发现
- CST的ADR率为40.43/100患者年,生物制剂为18.22/100患者年,CST高2.2倍(p<0.0001)。
- CST的药物相关停药率为0.16/患者年,生物制剂为0.02/患者年,CST高8.0倍(p<0.0001)。
- 女性总体ADR率显著高于男性:CST为57.30/100患者年 vs. 31.69/100患者年(1.8倍),生物制剂为27.36/100患者年 vs. 13.9/100患者年(2.0倍),p<0.0001。
- 女性多数CST的药物相关停药率更高。
关键数值与推荐
- 生物制剂组关节受累比例高于CST组(26.86% vs. 14.8%,p<0.0001)。
- CST的ADR率40.43/100患者年 vs. 生物制剂18.22/100患者年(p<0.0001)。
- 女性CST的ADR率57.30/100患者年 vs. 男性31.69/100患者年;女性生物制剂27.36/100患者年 vs. 男性13.9/100患者年(p<0.0001)。
临床怎么用
- 临床选择银屑病系统治疗时,应关注女性患者ADR风险更高,加强监测与个体化随访。
- 传统系统治疗的ADR和停药风险高于生物制剂,需权衡疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Psoriasis is a disease that often requires prolonged systemic treatment. It is important to determine the safety of available therapies. There is currently little insight into sex-specific differences in the safety of systemic psoriasis therapies. OBJECTIVES: To examine the real-world, long-term safety of systemic psoriasis therapies with sex stratification in drug-related adverse events (ADRs). METHODS: Ten-year data from adults with moderate-to-severe psoriasis requiring systemic treatment (conventional systemic therapies [CST], biologics) were obtained from the Swiss psoriasis registry (SDNTT). ADRs were categorized according to the international terminology Medical Dictionary for Regulatory Activities (MedDRA). Safety was assessed by calculating event rates per 100 patient-years (PY). We used descriptive statistics for patient and disease characteristics, and binomial and t-tests to compare treatment groups and sex. RESULTS: In total, 791 patients (290 females) were included with a mean age of 46 years. 358 (45%) received CSTs and 433 (55%) biologics; both groups had similar baseline characteristics except for more joint involvement in patients using biologics (26.86% vs. 14.8%, p < 0.0001). CSTs were associated with a 2.2-fold higher ADR rate (40.43/100 PY vs. 18.22/100 PY, p < 0.0001) and an 8.0-fold higher drug-related discontinuation rate than biologics (0.16/PY vs. 0.02/PY, p < 0.0001). Trends showed non-significant higher serious adverse event rates per 100 PY for biologics (8.19, CI 6.87-9.68) compared to CSTs (7.08, CI 5.39-9.13) (p = 0.3922). Sex stratification revealed a significantly higher overall ADR rate for all treatments in females (1.8-fold for CSTs [57.30/100 PY vs. 31.69/100 PY] and 2.0-fold for biologics [27.36/100 PY vs. 13.9/100 PY], p < 0.0001), and drug-related discontinuation rates for most CSTs in females. CONCLUSION: Females were associated with a significantly higher rate of ADRs and drug-related discontinuation rates. Sex stratification should be taken into consideration when designing studies in the patient-tailored management of psoriasis.
引用
- Verardi F, Maul LV, Borsky K, et al. Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry (SDNTT). J Eur Acad Dermatol Venereol. 2023. PMID: 38084852. doi:10.1111/jdv.19730
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。